Cuba encouraged by early trials of homegrown COVID-19 vaccine

A nurse shows a dose of the Soberana-02 COVID-19 vaccine to be used on a volunteer as part of Phase III trials with the Cuban experimental vaccine candidate amid concerns about the spread of coronavirus disease (COVID-19 ) in Havana, Cuba, March 31, 2021. Jorge Luis Banos / Pool via REUTERS

Havana, June 19 (Reuters) – Cuba’s vaccine candidate Soberana 2 has shown 62% effectiveness with just two of its three doses, state-owned biopharmaceutical company BioCubaFarma said Saturday, citing preliminary data from late-stage studies.

Cuba, which has a decades-old prestigious biotech sector, has five vaccine candidates in clinical trials, two of which – Soberana 2 and Abdala – are in late stage.

Reporting on Anett Rio’s letter from Sarah Marsh; Editing by David Gregorio

Our standards: The Thomson Reuters Trust Principles.

Comments are closed.